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INTRODUCTION
This chapter makes treatment recommendations for primary
IgAN. Secondary IgAN will not be discussed. The cost
implications for global application of this guideline are
addressed in Chapter 2.
10.1: Initial evaluation including assessment of risk of
progressive kidney disease
10.1.1: Assess all patients with biopsy-proven IgAN
for secondary causes of IgAN. (Not Graded)
10.1.2: Assess the risk of progression in all cases by
evaluation of proteinuria, blood pressure, and
eGFR at the time of diagnosis and during
follow-up. (Not Graded)
10.1.3: Pathological features may be used to assess
prognosis. (Not Graded)
BACKGROUND
IgAN is diagnosed by kidney biopsy and is defined as
dominant or codominant staining with IgA in glomeruli by
immunohistology.470 LN should be excluded. The intensity of
IgA staining should be more than trace. The distribution of
IgA staining should include presence in the mesangium, with
or without capillary loop staining. IgG and IgM may be
present, but not in greater intensity than IgA, except that
IgM may be prominent in sclerotic areas. C3 may be present.
The presence of C1q staining in more than trace intensity
should prompt consideration of LN.
IgAN is the most common primary GN in the world. The
prevalence rate varies across different geographical regions.
Typically, it is 30–35% of all primary glomerular diseases in
Asia, but can be up to 45%.471 In Europe, this is about
30–40%. Recently in the USA, IgAN was also reported to be
the most common primary glomerulopathy in young adult
Caucasians.472
Secondary IgAN is uncommon. Cirrhosis, celiac disease,
and HIV infection are all associated with a high frequency
of glomerular IgA deposition. IgAN has been infrequently
associated with a variety of other diseases, including
dermatitis herpetiformis, seronegative arthritis (particularly
ankylosing spondylitis), small-cell carcinoma, lymphoma
(Hodgkin lymphoma and T-cell lymphomas, including
mycosis fungoides), disseminated tuberculosis, bronchiolitis
obliterans, and inflammatory bowel disease (Crohn’s disease
and ulcerative colitis). These are usually clinically evident at
the time of biopsy. Investigations can include viral serologies
(HIV, HBV, and HCV), liver function tests, and electro-
phoreses of serum immunoglobulins.
IgAN has a wide spectrum of clinical presentations,
varying from isolated hematuria to rapidly progressive
GN. Thorough risk assessment is essential to determine
management and ensure that the risks of therapy are
balanced by the selection of patients at highest risk of
progression. Definitive outcomes in IgAN are kidney survival
and the rate of kidney function decline. Determinants of
mortality in IgAN have not been addressed in previous
studies, although it is reasonable to assume that CKD
increases cardiovascular morbidity and mortality in these
patients, as in others with CKD.473
RATIONALE
K There is moderate-quality evidence to suggest that
accelerated decline in kidney function is associated with
proteinuria Z1 g/d in a dose-dependent fashion and
independently of other risk factors.474–477
K There is moderate-quality evidence to suggest a favour-
able outcome when time-averaged proteinuria is reduced
to o1 g/d.477 Whether long-term outcome differs in
adult patients with a proteinuria between 0.5 and
1.0 g/d compared to o0.5 g/d remains uncertain. In
children, expert opinion suggests a goal of proteinuria
o0.5 g/d per 1.73m2.478
K There is moderate-quality evidence to recommend strict
blood pressure control, as it is associated with better
kidney survival in chronic proteinuric nephropathies,
including IgAN.
K There is low-quality evidence to suggest GFR at
presentation is associated with the risk of ESRD.
However, studies that have assessed the rate of change
of kidney function have questioned its association with
initial GFR. Proteinuria, blood pressure, and kidney
biopsy findings at presentation have been associated with
both risk of ESRD and doubling of SCr.
K There is low-quality evidence to suggest kidney biopsy
findings associated with a worse prognosis are the
presence and severity of mesangial and endocapillary
proliferation, extensive crescents, focal and segmental as
well as global glomerulosclerosis, tubular atrophy, and
interstitial fibrosis.470,479 However, no single approach to
the objective evaluation of biopsy findings has yet been
validated or evaluated prospectively.
K There is moderate-quality evidence to suggest that IgAN
that presents with hematuria and minimal proteinuria is
a progressive disease, and that life-long follow-up with
regular monitoring of blood pressure and proteinuria is
recommended.480
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Proteinuria is the strongest prognostic factor in IgAN and has
a ‘‘dose-dependent’’ effect that is independent of other risk
factors in multiple large observational studies, as well as
prospective trials. The threshold above which the risk
develops in adults is uncertain; some studies indicate
0.5 g/d481 while others could only demonstrate a higher risk
of ESRD and a more rapid rate of decline in kidney function
when time-averaged proteinuria was above 1 g/d.474,477 A
large observational study demonstrated that a reduction of
proteinuria to o1 g/d carried the same favorable impact on
long-term outcome, whether the initial value was 1–2 g/d,
2–3 g/d, or 43 g/d.477 Other surrogates of long-term out-
come, such as a 50% decline in proteinuria, have been
used.482 In children, observational studies have also con-
sistently shown a relationship between the level of protein-
uria and outcome, but did not assess a threshold value.
Expert opinions in children advocate a cut-off of 0.5 g/d per
1.73m2 for partial remission, and 0.16 g/d per 1.73m2 for
complete remission; these thresholds have been used in
RCTs.478,483
Uncontrolled hypertension during follow-up is asso-
ciated with greater proteinuria and predicts a faster GFR
decline.484,485 As in other proteinuric chronic glomerulo-
pathies, a blood pressure goal o130/80mm Hg in patients
with proteinuria 40.3 g/d, and o125/75mm Hg when
proteinuria is 41 g/d, is recommended.486,487
The GFR at presentation has consistently been related to
the risk of ESRD. Whether a lower GFR is also accompanied
by a faster rate of kidney function decline is questionable;
two observational studies have failed to show this relation-
ship.475,488 Proteinuria, blood pressure, and pathological
features should take precedence over initial GFR in the
estimation of the future rate of kidney function decline.
Numerous studies have addressed the predictive value of
pathology findings. Mesangial489,490 and endocapillary pro-
liferation,479,491 extensive crescents,492–495 FSGS,496,497 global
glomerulosclerosis, tubular atrophy, and interstitial fibro-
sis479,491,493,496 are associated with a more rapid rate of
deterioration and lower kidney survival using univariate and,
at times, multivariate analysis adjusting for clinical assess-
ment. The recent Oxford Classification of IgAN has
demonstrated the importance of (i) mesangial hypercellular-
ity; (ii) segmental glomerulosclerosis; (iii) endocapillary
hypercellularity; and (iv) tubular atrophy/interstitial fibrosis,
as independent pathological variables predicting kidney
outcome.479 This may become the standard, but requires
validation before it can be recommended in routine clinical
practice. Whether classification of the disease in this manner
should impact treatment choice has also not been deter-
mined.
Obesity has been identified as an independent risk factor
for the appearance of ESRD,498 and weight loss induces a
significant decrease in proteinuria.499 Some observational
studies500,501 have reported an increased risk of greater
proteinuria, more severe pathological lesions, and ESRD
among IgAN patients who are overweight (BMI425 kg/m2).
Other risk factors have also been studied. Outcomes do not
differ between sexes.217 Children are less likely to reach ESRD
compared to adults, but this may be because GFR is higher at
presentation in children, even though there is a similar rate
of kidney function decline. Different biopsy and treatment
practices in the pediatric population limit comparisons to
adults. Since the risk factors presented above have been
validated in both children and adults, clinicians should
consider these before the age of the patient. Similarly, it is
uncertain whether geographical or ethnic variations in
outcomes are secondary to different biopsy and treatment
practices or variations in disease severity.475 Macroscopic
hematuria is more frequent in children, and some studies have
associated its presence with a favorable outcome, while others
have shown this benefit to be confounded by a higher initial
GFR and earlier detection with no independent value.502,503
10.2: Antiproteinuric and antihypertensive therapy
10.2.1: We recommend long-term ACE-I or ARB
treatment when proteinuria is 41 g/d, with
up-titration of the drug depending on blood
pressure. (1B)
10.2.2: We suggest ACE-I or ARB treatment if protein-
uria is between 0.5 to 1 g/d (in children,
between 0.5 to 1 g/d per 1.73 m2). (2D)
10.2.3: We suggest the ACE-I or ARB be titrated
upwards as far as tolerated to achieve protei-
nuria o1 g/d. (2C)
10.2.4: In IgAN, use blood pressure treatment goals of
o130/80 mm Hg in patients with proteinuria
o1 g/d, and o125/75 mm Hg when initial
proteinuria is 41 g/d (see Chapter 2). (Not
Graded)
RATIONALE
Many of the trials using ACE-I/ARBs in IgAN recruited
patients with proteinuria Z1 g/d478,504 while some recruited
patients with proteinuria Z0.5 g/d.505
In registry data,477 the rate of decline of function increased
with the amount of proteinuria; those with sustained
proteinuria Z3 g/d lost kidney function 25-fold faster than
those with proteinuria o1 g/d. Patients who presented with
Z3 g/d who achieved proteinuria o1 g/d had a similar
course to patients who hado1 g/d throughout, and fared far
better than patients who never achieved this level. There is,
as yet, no evidence in IgAN that reducing proteinuria below
1 g/d in adults gives additional benefit.
Several RCTs478,504–506 have shown that ACE-I and ARBs
can reduce proteinuria and improve kidney function
(assessed by reduction of the slope of GFR deterioration;
Online Suppl Table 44). However, there is, as yet, no
definitive study of sufficient duration to show the benefit of
either ACE-I or ARBs in reducing the incidence of ESRD.
There are no data to suggest preference of ACE-I over
ARBs, or vice versa, except in terms of a lesser side-effect
profile with ARBs compared to ACE-I.
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One study507 suggested the combination of ACE-I and
ARBs induced a 73% greater reduction of proteinuria than
monotherapy (ACE-I 38% and ARB 30%, respectively). A
small study of seven pediatric IgAN patients also showed
some benefits508 with a combination of ACE-I and ARB.
However, more studies are needed to determine whether the
definite benefit of combination therapy is effective, leading to
a better kidney outcome.
RESEARCH RECOMMENDATION
K RCTs are needed to compare the efficacy in proteinuric
IgAN of combination therapy using ACE-I and ARBs to
monotherapy using either alone.
10.3: Corticosteroids
10.3.1: We suggest that patients with persistent
proteinuria Z1 g/d, despite 3–6 months of
optimized supportive care (including ACE-I or
ARBs and blood pressure control), and GFR
450 ml/min per 1.73 m2, receive a 6-month
course of corticosteroid therapy. (2C)
RATIONALE
K There is low-quality evidence that corticosteroids provide
an additional benefit to optimized supportive care
(Online Suppl Table 47).
K A 6-month corticosteroid regimen can follow either of
two regimens, which have been used in published trials
(see Table 26).
K There is no evidence to suggest the use of corticosteroids
in patients with GFR o50ml/min.
K The available studies do not allow recommendations for
preferred dosage regimens. The studies did not report
serious side-effects. However, there are other studies with
similar regimens in non-IgAN patients that suggest more
side-effects with high-dose pulse corticosteroids, includ-
ing hypothalamic-pituitary-adrenal axis suppression and
acute myopathies.
Few RCTs so far have tested the efficacy of a cortico-
steroid regimen vs. no immunosuppressive therapy. In an
Italian trial,509 a 6-month course of corticosteroids led
to better clinical disease remission and long-term out-
come512 than no steroids. However, only about 15% of the
patients had received an ACE-I at randomization,509 and
blood pressure control was not optimal by contemporary
standards.513
Two more recent RCTs510,511,514 used oral prednisone
added to an ACE-I and compared this to an ACE-I alone. In
the Italian study,510 the mean annual GFR loss was reduced
from about 6ml/min to 0.6ml/min, and in the Chinese
study511 the proportion of patients with a 50% increase in
SCr decreased from 24% to 3% with corticosteroid therapy. A
major limitation of both studies is that all ACE-I and ARBs
had to be halted for 1 month prior to study inclusion, and
then an ACE-I was started together with corticosteroids in
the combination group. Therefore, a number of low-risk
patients may have been included, who would have achieved
proteinuria o1 g/d with ACE-I therapy alone. A further
potential confounder is that both studies included patients
who had received prior immunosuppression. An American
trial in adults and children, all of whom received an
ACE-I, also noted reduced proteinuria with corticosteroids
(60mg/m2 prednisone every other day tapered to 30mg/m2
at 12 months) but no difference in kidney function was
observed at 2 years.515
A Japanese RCT that used low-dose corticosteroids
(20mg/d prednisolone, tapered to 5mg/d by 2 years)
observed no benefit on kidney function, despite reduced
proteinuria with the corticosteroid regimen.516
Subjects with IgAN and GFRo50ml/min were either
excluded from these trials509,514 or were few in number,511 so
that currently, there are no data to assess the value of
corticosteroids in this population.
A recent meta-analysis517 concluded that corticosteroids
reduce doubling of SCr. However, in that analysis, 85% of the
weight was contributed by two studies,509,518 both of which
lacked optimal antiproteinuric and antihypertensive therapy
based on contemporary standards. Of note, an American
RCT in children and adults with IgAN515 noted no difference
in reaching the endpoint (440% decrease in GFR) between
a group receiving ACE-I only vs. ACE-I plus prednisone
(60mg/m2 per 48 hours for 3 months, reduced to 30mg/m2
per 48 hours at month 12). However, few end-points were
reached in this trial; thus, it was underpowered to detect
small differences.
RESEARCH RECOMMENDATION
K Studies using immunosuppressive agents should always
include rigorous blood pressure control and antiprotei-
nuric therapy. This is currently being tested in the STOP-
IgAN trial.519 Newer immunosuppressives (alone or in
combination) should be compared in RCTs to a ‘‘control’’
group receiving corticosteroids alone.
Table 26 | Corticosteroid regimens in patients with IgAN
References Pozzi C et al.509 Manno C et al.510; Lv J et al.511
Regimen i.v. bolus injections of 1 g methylprednisolone for 3 days each
at months 1, 3, and 5, followed by oral steroid 0.5mg/kg
prednisone on alternate days for 6 months
6-month regime of oral prednisonea starting with 0.8–1mg/kg/d for
2 months and then reduced by 0.2mg/kg/d per month for the next
4 months
IgAN, immunoglobulin A nephropathy.
aPrednisone and prednisolone are equivalent and can be used interchangeably with the same dosing regimen.
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10.4: Immunosuppressive agents (cyclophosphamide,
azathioprine, MMF, cyclosporine)
10.4.1: We suggest not treating with corticosteroids
combined with cyclophosphamide or azathio-
prine in IgAN patients (unless there is cres-
centic IgAN with rapidly deteriorating kidney
function; see Recommendation 10.6.3). (2D)
10.4.2: We suggest not using immunosuppressive
therapy in patients with GFR o30 ml/min
per 1.73 m2 unless there is crescentic IgAN
with rapidly deteriorating kidney function
(see Section 10.6). (2C)
10.4.3: We suggest not using MMF in IgAN. (2C)
RATIONALE
Please consult Online Suppl Tables 51–60
K There is very low–quality evidence from a single RCT in
high-risk adults to use a combination of prednisolone
(40mg/d reduced to 10mg/d by 2 years) and cyclophos-
phamide (1.5mg/kg/d) for 3 months, followed by
azathioprine (1.5mg/kg/d) for a minimum of 2 years.
This study showed a better kidney survival over controls
in a highly selected group of patients.
K There is insufficient evidence that immunosuppressive
agents other than steroids used as first-line therapy offer
an advantage or equivalence compared to steroids.
K The risk-benefit assessment is strongly impacted by the
potential for severe adverse effects of these drugs.
Despite retrospective studies in IgAN supporting the use
of immunosuppressive therapy other than corticosteroids,
few RCTs have demonstrated a benefit. An RCT using
corticosteroids combined with cyclophosphamide, followed
by azathioprine, included a highly selected group of patients
with SCr 41.47–2.83mg/dl (4130–250 mmol/l) with a 15%
increase within the last year, and initial proteinuria 3.9±0.8
and 4.6±0.4 g/d in the treatment and control groups,
respectively. The active treatment group achieved lower
proteinuria, a 4-fold lower rate of kidney function decline,
and a much greater kidney survival (72% 5-year survival
compared to 6% in controls, P¼ 0.006). There are limitations
in the applicability of the findings: (i) there was no steroid
monotherapy arm; (ii) the use of RAS blockade was not
detailed but these agents could not be initiated after the start
of the trial; (iii) the follow-up blood pressure was higher than
recommended by current guidelines.
Two RCTs compared cyclophosphamide, dipyridamole,
and warfarin to controls and found no benefit.520,521 Given
these results and the potential side-effects, we do not suggest
the use of cyclophosphamide monotherapy.
Azathioprine
Two RCTs, one in children and another in children and
adults, tested azathioprine and corticosteroids in patients
with preserved kidney function. They demonstrated a
reduction in chronic lesions compared to controls on repeat
biopsy.483,522 Monotherapy with steroids has been shown to
preserve kidney function (a plausible surrogate for reduced
chronic lesions). In a recent trial in patients with IgAN,523
adding low-dose azathioprine for 6 months did not increase
the benefit of corticosteroids alone, but did increase the
occurrence of adverse events.
A study in 80 children with newly diagnosed IgAN524
compared the effects of the combination of prednisolone,
azathioprine, warfarin, and dipyridamole with those of
prednisolone alone. There was complete remission of
proteinuria (o0.1 g/m2/d) in 36 (92.3%) of the 39 patients
who received the combination and 29 (74.4%) of the 39 who
received prednisolone alone (P¼ 0.007). Some side-effects
were observed including leucopenia, glaucoma, and aseptic
necrosis. The percentage of sclerosed glomeruli was un-
changed in the patients who received the combination, but
increased in the prednisolone group. In summary of these
studies, we do not suggest the addition of azathioprine to
corticosteroids for the treatment of IgAN.
An RCT compared 6 months of treatment with cortico-
steroids plus azathioprine or corticosteroids alone in 207
IgAN patients with plasma creatinine r2.0mg/dl
(r177 mmol/l) and proteinuria Z1 g/d. After a median
follow-up of 4.9 years, a 50% increase in plasma creatinine
from baseline occurred in 13% of the combination group and
11% of the monotherapy group (P¼ 0.83); effects on
proteinuria and 5-year cumulative kidney survival were also
similar in both groups (88% vs. 89%; P¼ 0.83). Treatment-
related adverse events were more frequent in the combination
group (17%) as compared to the monotherapy group (6%;
P¼ 0.01). Thus, in this study, 6 months of treatment with
azathioprine did not increase the benefit obtained from
steroids alone, but increased the occurrence of adverse
events.523
MMF
The findings from RCTs studying MMF in IgAN are variable.
A Belgian study525 assessed MMF 2 g/d for 3 years vs. placebo
in 34 patients with an average initial inulin clearance of
70ml/min per 1.73m2 and proteinuria of 1.8 g/d. No
difference in proteinuria reduction or preservation of GFR
was observed. Similarly, a North American study482 found no
benefits over 24 months using a 1-year regimen of MMF 2 g/d
vs. placebo in 32 patients with an initial GFR of 40ml/min
per 1.73m2 and a proteinuria of 2.7 g/d. In contrast, a
Chinese study in 40 patients with a mean initial GFR of
72ml/min per 1.73m2 and mean proteinuria 1.8 g/d found a
significant reduction in proteinuria at 18 months with MMF
given for 6 months over controls.526 A 6-year follow-up of the
same cohort demonstrated a kidney survival benefit.527 No
steroid was given in these trials, and all patients received
ACE-I. The results of these studies are too heterogeneous to
suggest the use of MMF at the present time. The reasons for
heterogeneity of outcome require further investigation, but
different ethnicity or differences in drug levels achieved may
be contributory factors. Of note is a retrospective cohort
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study that suggested delayed severe pneumonia could occur
in MMF-treated patients with IgAN.528 The potential side-
effects of using MMF and the heterogeneity of outcomes
from these data require better-performed studies before this
drug can be recommended as first-line therapy.
Steroid Resistance
The approach to patients, who have no benefit in response
to corticosteroids added to optimal antihypertensive and
antiproteinuric therapy is unknown; no relevant RCTs have
been conducted.
RESEARCH RECOMMENDATIONS
K An RCT is needed comparing MMF and corticosteroids
vs. corticosteroids alone in patients receiving optimal
antihypertensive and antiproteinuric therapy.
K An RCT is needed to investigate the different efficacy of
MMF in Asians vs. Caucasians, including evaluation of
drug and metabolite levels.
10.5: Other treatments
10.5.1: Fish oil treatment
10.5.1.1: We suggest using fish oil in the
treatment of IgAN with persistent
proteinuria Z1 g/d, despite 3–6
months of optimized supportive care
(including ACE-I or ARBs and blood
pressure control). (2D)
BACKGROUND
Fish oil supplements have shown a number of beneficial
cardiovascular effects, including systolic blood pressure and
triglyceride lowering, reduced resting heart rate, improve-
ment in several markers of endothelial damage, and
reduction in the risk of sudden cardiac death in patients
with established coronary heart disease. Several RCTs have
evaluated the effect of fish oil in IgAN.
RATIONALE
Please consult Online Suppl Tables 61–64.
K There is mostly low-quality evidence that suggests using
fish oil supplements in patients with IgAN, but the RCTs
evaluating this therapy have reported conflicting results.
However, given the very low risk profile and the
potentially beneficial cardiovascular effects, fish oil can
be considered a very safe treatment.
In a trial that included 106 patients, fish oil treatment
(12 g/d) improved kidney survival and retarded the rate of
kidney function loss, without significant reduction of
proteinuria.529 Of note, the outcome of the control group,
treated with 12 g/d of olive oil was poor (cumulative
incidence of death or ESRD after 4 years was 10% in fish
oil–treated patients, 40% in the control group). Longer
follow-up confirmed the beneficial influence of fish oil
treatment in this study.530 Another RCT including 34 patients
reported a beneficial influence of fish oil (3 g/d) on two end-
points: the risk of ESRD, and Z50% increase in SCr.531 In
this study, fish oil reduced proteinuria significantly. In a
short-term (6-month) RCT, a significant proteinuria reduc-
tion was observed in patients treated with a combination of
ACE-I and ARB plus fish oil (3 g/d) in comparison to a
control group that received only ACE-I and ARB (percentage
of patients withZ50% proteinuria reduction, 80% and 20%,
respectively).532
In contradiction to these studies, other RCTs failed to detect
a significant benefit of fish oil treatment.533,534 A meta-
analysis535 concluded that fish oils are not beneficial in IgAN,
although another meta-analysis that combined clinical trials
focused on IgAN, diabetes, lupus nephritis, and other
glomerular diseases showed a greater proteinuria decrease
in patients treated with fish oil, without changes in renal
function.536 A more recent RCT compared steroids (33
patients), fish oil (4 g/d, 32 patients), and placebo (31 patients)
for 2 years.515 Neither treatment group showed benefit over the
placebo group. However, patients in the placebo group had a
statistically significant lower degree of proteinuria at baseline.
In trying to explain these discordant results, some authors
have proposed that the effects of fish oil in IgAN patients
could be dosage-dependent.537 However, another prospective
trial reported that high (6.7 g/d) and low (3.3 g/d) doses of
fish oil were similar in slowing the rate of kidney function
loss in high-risk IgAN patients.538 At present, there is no
evidence to support the use of high-dose fish oil in IgAN.
We suggest fish oil (3.3 g/d) can be considered in the
treatment of IgAN with persistent proteinuria Z1 g/d,
despite 3–6 months of optimized supportive care (including
ACE-I or ARBs and blood pressure control).
RESEARCH RECOMMENDATION
K An RCT is needed of fish oil in IgAN to examine
preserved kidney function with persistent significant
proteinuria, despite optimal antihypertensive and anti-
proteinuric therapy.
10.5.2: Antiplatelet agents
10.5.2.1: We suggest not using antiplatelet
agents to treat IgAN. (2C)
RATIONALE
Please consult Online Suppl Table 65.
K There is low-quality evidence to recommend not using
antiplatelet therapy in IgAN.
A meta-analysis539 based on seven studies, most of them
performed in Japan, concluded that antiplatelet therapy
resulted in reduced proteinuria and protected kidney
function in patients with moderate to severe IgAN. However,
there were significant limitations of the evidence in this meta-
analysis, due to suboptimal quality of individual controlled
trials. Importantly, the effect of antiplatelet agents alone
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could not be discerned because patients received other
concomitant therapies. Thus, in three studies, both treatment
and control groups received other agents, including cyto-
toxics, steroids, antihypertensive agents, and anticoagulants.
In three other studies, the intervention group received
warfarin (two studies) and aspirin (one study) in addition
to the antiplatelet agent (dipyridamole). Dipyridamole was
the most commonly used antiplatelet agent (five studies)
followed by trimetazidine and Dilazep (one study each).
RESEARCH RECOMMENDATION
K A multicenter RCT is needed to address the role of
antiplatelet therapy in IgAN.
10.5.3: Tonsillectomy
10.5.3.1: We suggest that tonsillectomy not be
performed for IgAN. (2C)
RATIONALE
K There is low-quality evidence to suggest not using
tonsillectomy as treatment for IgAN. No RCT has been
performed of tonsillectomy for IgAN.
Tonsillectomy may be indicated in those with IgAN for
conventional reasons, e.g., recurrent bacterial tonsillitis.
Clinical judgment needs to be exercised to decide whether
to perform tonsillectomy in a very selected group of patients
with a close relationship between paroxysm of gross
hematuria and tonsillitis. However, only retrospective
analyses540,541 as well as one nonrandomized trial542 have
reported a better outcome for IgAN after tonsillectomy. In
these studies, tonsillectomy was often combined with other—
in particular, immunosuppressive—treatment;540–542 thus,
the specific value of tonsillectomy is not always apparent.
Furthermore, in other retrospective series, investigators failed
to note a benefit from tonsillectomy.543
RESEARCH RECOMMENDATION
K A multicenter RCT is needed to address the role of
tonsillectomy in IgAN.
10.6: Atypical forms of IgAN
10.6.1: MCD with mesangial IgA deposits
10.6.1.1: We recommend treatment as for
MCD (see Chapter 5) in nephrotic
patients showing pathological find-
ings of MCD with mesangial IgA
deposits on kidney biopsy. (2B)
BACKGROUND
Patients with IgAN can present with proteinuria within the
nephrotic range (43.5 g/d), and it portends a poor prog-
nosis if this high-grade proteinuria persists during
follow-up. However, the typical accompanying findings of
complete nephrotic syndrome (edema, hypoalbuminemia,
hyperlipidemia) are uncommon. Rarely, some patients with
nephrotic syndrome have been identified in whom kidney
biopsy shows minimal glomerular changes by light micro-
scopy, diffuse podocyte foot process effacement on electron
microscopy, and predominant mesangial deposits of IgA
on immunofluorescence. A coincidence of two different
glomerular diseases (minimal-change nephrotic syndrome
and IgAN) has been proposed as the most likely explanation
for such cases.
RATIONALE
K There is low-quality evidence to recommend that patients
with nephrotic syndrome and coincidental histological
findings of MCD and IgAN should be treated like
patients with MCD.
Several series544,545 have described prompt, complete remis-
sions after corticosteroid therapy in a majority of patients
with nephrotic syndrome and a pathological diagnosis of
coincidental MCD and IgAN. This initial treatment response
and the following clinical course, with a frequent appearance
of nephrotic syndrome relapses, are very reminiscent of that
of patients with pure MCD. An RCT in IgAN patients with
nephrotic proteinuria546 also showed a high percentage of
complete remission in patients with such characteristics.
10.6.2: AKI associated with macroscopic hematuria
10.6.2.1: Perform a repeat kidney biopsy in
IgAN patients with AKI associated
with macroscopic hematuria if, after
5 days from the onset of kidney
function worsening, there is no im-
provement. (Not Graded)
10.6.2.2: We suggest general supportive care for
AKI in IgAN, with a kidney biopsy
performed during an episode of macro-
scopic hematuria showing only ATN
and intratubular erythrocyte casts. (2C)
BACKGROUND
Episodic macroscopic hematuria coinciding with mucosal
(usually upper respiratory) infections are typical of IgAN.
The macroscopic hematuria usually resolves spontaneously in
a few days, but in some cases it can persist for several
weeks.547 The development of AKI during macroscopic
hematuria episodes is uncommon547,548 but represents the
first manifestation of IgAN in some patients.
RATIONALE
K ATN and intratubular erythrocyte casts are the most
common pathological findings in kidney biopsies during
AKI accompanying macroscopic hematuria episodes
in IgAN.
K Kidney function usually, but not always, recovers
completely after the disappearance of macroscopic
hematuria.
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K Kidney biopsy allows differentiation of tubular damage
and tubular occlusion by erythrocyte casts from crescen-
tic IgAN or other coincidental causes of AKI.
Kidney biopsies performed during an episode of macroscopic
hematuria typically show mesangial proliferation and occa-
sional segmental crescents.549 In those cases with AKI
coincidental with gross hematuria, the glomerular changes
are usually insufficient to account for the AKI. Hematuria by
itself may be responsible for the AKI, through tubular injury
that is induced by intratubular erythrocytic casts and a
possible nephrotoxic effect of the hemoglobin that is released
from these casts. Features of ATN and tubules filled by red
blood cells are the most relevant histological findings. In a
majority of patients, kidney function returns to baseline after
the disappearance of macroscopic hematuria,547–549 but
incomplete recovery of kidney function has been described
in up to 25% of affected patients.547 Duration of macroscopic
hematuria longer than 10 days is the most significant risk
factor for persistent kidney impairment.547 Continuous
supportive care, as in other types of ATN, is the recom-
mended therapeutic approach to these patients. There is no
information about the usefulness of corticosteroids in
patients with more severe forms of AKI or longer duration
of macroscopic hematuria.
However, some patients with AKI and macroscopic
hematuria exhibit a crescentic form of IgAN (crescents affecting
450% of glomeruli), whose prognosis is considerably
worse.492–495 A repeat kidney biopsy is suggested in patients
with known IgAN who present a protracted AKI accompanying
a new episode of gross hematuria, in order to differentiate ATN
from crescentic IgAN or other types of AKI (Algorithm 1).
10.6.3: Crescentic IgAN
10.6.3.1: Define crescentic IgAN as IgAN with
crescents in more than 50% of glo-
meruli in the renal biopsy with
rapidly progressive renal deteriora-
tion. (Not Graded)
10.6.3.2: We suggest the use of steroids and cyclo-
phosphamide in patients with IgAN
and rapidly progressive crescentic IgAN,
analogous to the treatment of ANCA
vasculitis (see Chapter 13). (2D)
BACKGROUND
Crescentic IgAN has a poor prognosis. In a historical group
of 12 untreated crescentic IgAN patients, about 42% reached
ESRD in 36 months.495 Another Japanese study showed that
patients with 450% crescents developed ESRD in 75% of
AKI and macroscopic hematuria 
Renal biopsy 
Causes other than IgAN: 
(Crescentic GN, vasculitis, 
LN, postinfectious GN) 
IgAN
(Dominant or codominant 
staining with IgA in glomeruli 
by immunohistology) 
ATN and intratubular 
erythrocytic casts as the 
most remarkable 
histological lesions 
Crescentic IgAN 
(Crescents in >50% of 
glomeruli)
Supportive treatment as in 
other types of ATN.
Steroids and 
cyclophosphamide as in 
crescentic ANCA vasculitis 
Repeated episodes of AKI accompanying 
macroscopic hematuria: Consider a kidney 
biopsy when no improvement of kidney 
function is observed after at least 5 days from 
the onset of kidney function worsening. 
Algorithm 1 |Management algorithm of patients with AKI associated with macroscopic hematuria.
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patients by 10 years follow-up.550 In this study, the patients
were divided into four groups: group 1, absence of crescents
and fibrous adhesion of glomerular tufts to Bowman’s
capsule; group 2, less than 25%; group 3, 25-50%; group 4,
more than 50%. Ten-year renal survival rates were 100% in
group 1, 94.3% in group 2, 81.8% in group 3, and 25.5% in
group 4, respectively, indicating that patients with 450%
crescents in glomeruli had a much worse survival than those
with r50% glomerular crescents.
The outcome of IgAN with diffuse crescent formation has
also been studied in 25 Chinese IgAN patients.551 Most of
them showed rapidly progressive GN associated with more
severe pathological changes, including glomerular, tubular
interstitial, and vascular lesions, than in patients with general
IgAN. The infiltrates in glomeruli may contribute to the
crescentic formation. Diffuse crescent formation was defined
by 50% or more of the glomeruli affected.551 The
pathological diagnosis of crescentic IgAN has not been
unified among these studies. While some use crescents
involving over 50% of glomeruli as the definition,551 others
use the presence of incipient to fulminant cellular crescents,
with or without segmental endocapillary proliferation in
410% of glomeruli.495 Although there is insufficient
evidence for a unifying definition, we suggest a definition
of crescentic IgAN as both a pathological finding of over 50%
glomeruli having crescents and the clinical feature of rapidly
progressive deterioration of renal function.
A recent study of 67 patients552 with vasculitic IgAN (33
HSP, 34 IgAN) showed that three factors significantly affected
kidney outcome: kidney function, blood pressure at pre-
sentation, and the amount of chronic damage in the biopsy.
RATIONALE
K There is no RCT of treatment in crescentic IgAN.
The three largest observational studies495,551,552 all concluded
that immunosuppression is potentially useful. In a study of
25 patients with diffuse crescentic IgAN treated with
immunosuppression, 67% of patients maintained sufficient
kidney function to avoid renal replacement therapy, four had
SCr o1.4mg/dl (o124 mmol/l), and only five were dialysis-
dependent. In another study, although an improved out-
come was seen in those receiving immunosuppression, the
conclusions were cautious, as the treated and untreated
groups were not comparable. The third study also suggested
positive effects of immunosupression.495 This study used
i.v. methylprednisolone 15mg/kg/d for 3 days and monthly
i.v. cyclophosphamide 0.5 g/m2 for 6 months. Twelve
treated patients were compared to 12 historical controls.
After 36 months, the rate of ESRD in the treated group was
lower (one out of 12) than in the historical controls (five out
of 12).
Recommended therapeutic regimens in these reports are
varied, but initial therapy has usually included high-dose
oral or i.v. corticosteroids plus oral or i.v. cyclophos-
phamide. In one study, some patients were changed from
cyclophosphamide to azathioprine at 3 months. Durations of
treatment in these three series varied from 3 to 24 months.
There is only poor-quality evidence to support the use of
plasma exchange. One anecdotal report indicated benefit in
five patients using plasma exchange in a combination of
immunosuppressive therapies.553
RESEARCH RECOMMENDATION
K RCTs are needed to investigate the benefits of cyclophos-
phamide, MMF, and azathioprine in crescentic IgAN.
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